IQVIA: when 'trust' is the product, old regulator artefacts can still be live ammunition for a short
The Opportunity
Upstream still makes this a SHORT, and the logic is reputational rather than mechanical: if a data or compliance narrative sticks to a company whose business is regulated information and execution, the downside is nonlinear because customers de-risk by cutting exposure, not by trimming budgets. The key nuance is that the most concrete regulator artefact surfaced is old, so this is not a 'new enforcement' trade; it is a 'trust overhang can resurface and reprice' trade, expressed directly in IQV rather than via a basket.
The Timing
Freshness is 30 with a staleness flag, so timing risk is high: this can sit dead until a new article, a new filing, or a new enforcement cycle references the older issue and makes it current again. In a crosswind regime, that means you do not have clean tape support - you are trading for narrative re-emergence. The confirmation required to upgrade this is a 2026-dated primary trigger (FDA, DOJ, SEC risk-factor change) that makes the issue present-tense.
The Evidence
The strongest surfaced primary artefact is an FDA notice about quality problems in data provided by IQVIA used to inform estimates for some controlled substances, but upstream due diligence explicitly flags it as an older (2018-era) anchor ( fda.gov ). The other surfaced content is strategy-style Hatch-Waxman material that reads as educational rather than a discrete trigger ( drugpatentwatch.com ).